RankingsPricing
  1. US-listed companies
  2. Travere Therapeutics, Inc.

Travere Therapeutics, Inc.TVTX

Market cap
$1.1B
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Feb 29,
2012		Dec 31,
2012		Dec 31,
2013		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023
Net loss-14,825-30,343,856-33,823,509117-48-60-103-146-169-180-278-111
Depreciation and amortization-125,240341,233131618192025273339
Share based compensation-18-262927202124313944
Net Change in Fair Value of Contingent Consideration--------342215-
Loss on extinguishment of debt----4---17----8-
Payments from change in fair value of contingent consideration---14181912--12-14-9-
Inventory Write-down---------223
Loss on extinguishment of debt----4---17----8-
Amortization of debt discount and issuance costs---111310101122
Inventory Write-down---------223
Amortization of (discounts) premiums on investments-------1-1-2-7
Amortization of debt discount and issuance costs---111310101122
Other------100-1-5-14
Acquired IPR&D expense--------97---
Accounts receivable---56-5-05-20111
Inventory---1023252239
Tax receivable--------16-1700
Prepaid expenses and other current and non-current assets--1123184155
Change in lease assets and liabilities, net---------16-1-1
Accounts payable-1-----39-632-
Accounts payable--63103-----25
Accrued expenses----------2222
Deferred revenue, current and non-current---------38-13-16
Other current and non-current liabilities-----------2-0
Other------100-1-5-14
Accounts receivable---56-5-05-20111
Inventory---1023252239
Tax receivable--------16-1700
Prepaid expenses and other current and non-current assets--1123184155
Change in lease assets and liabilities, net---------16-1-1
Accounts payable-1-----39-632-
Accounts payable--63103-----25
Accrued expenses----------2222
Deferred revenue, current and non-current---------38-13-16
Other current and non-current liabilities-----------2-0
Net income from discontinued operations-----------265
Net cash used in operating activities-49-2,736,739-17,589,168--7-25-58-43-15-186-280
Net loss from continuing operations-0.14-----------376
Depreciation and amortization-125,240341,233131618192025273339
Share based compensation-18-262927202124313944
Net Change in Fair Value of Contingent Consideration--------342215-
Loss on extinguishment of debt----4---17----8-
Payments from change in fair value of contingent consideration---14181912--12-14-9-
Inventory Write-down---------223
Loss on extinguishment of debt----4---17----8-
Amortization of debt discount and issuance costs---111310101122
Inventory Write-down---------223
Amortization of (discounts) premiums on investments-------1-1-2-7
Amortization of debt discount and issuance costs---111310101122
Other------100-1-5-14
Acquired IPR&D expense--------97---
Accounts receivable---56-5-05-20111
Inventory---1023252239
Tax receivable--------16-1700
Prepaid expenses and other current and non-current assets--1123184155
Change in lease assets and liabilities, net---------16-1-1
Accounts payable-1-----39-632-
Accounts payable--63103-----25
Accrued expenses----------2222
Deferred revenue, current and non-current---------38-13-16
Other current and non-current liabilities-----------2-0
Other------100-1-5-14
Accounts receivable---56-5-05-20111
Inventory---1023252239
Tax receivable--------16-1700
Prepaid expenses and other current and non-current assets--1123184155
Change in lease assets and liabilities, net---------16-1-1
Accounts payable-1-----39-632-
Accounts payable--63103-----25
Accrued expenses----------2222
Deferred revenue, current and non-current---------38-13-16
Other current and non-current liabilities-----------2-0
Net cash used in operating activities - continuing operations----1-2-------325
Net cash provided by operating activities - discontinued operations-----------45
Net cash used in operating activities-49-2,736,739-17,589,168--7-25-58-43-15-186-280
Proceeds from the sale/maturity of marketable debt securities----------382335
Purchase of marketable debt securities--4199184102331224215547385444
Purchase of fixed assets--24,774144,679011107501
Purchase of intangible assets--1,168,093571013191518192842
Purchase of IPR&D, net of cash acquired---331---95---
Other----------1-
Other----------1-
Net cash used in investing activities - continuing operations----8110-------152
Net cash provided by (used in) investing activities-2-5,406,425--46-20320-61-138-3356
Net cash provided by investing activities - discontinued operations-----------207
Net cash provided by (used in) investing activities-2-5,406,425--46-20320-61-138-3356
Payment of guaranteed minimum royalty-------22222
Payment of business combination-related contingent consideration-----4103862-
Proceeds from Convertible Debt----------316-
Proceeds from Convertible Debt----------316-
Payment of debt issuance costs----------10-
Payment of debt issuance costs----------10-
Repurchase of 2025 convertible senior notes including premium----------211-
Repurchase of 2025 convertible senior notes including premium----------211-
Underwritten Equity Offering--------109---
At-The-Market Offering--------23---
At-The-Market Offering--------23---
Proceeds from Issuance of Common Stock-435149-------191
Proceeds from Stock Options Exercised---74811241353
Proceeds from Issuance of Warrants---4645----25
Proceeds from Stock Plans----------33
Proceeds from Stock Options Exercised---74811241353
Underwritten Equity Offering---------189--
At-The-Market Offering---------3620-
At-The-Market Offering---------3620-
Proceeds from Stock Plans----------33
Net cash provided by financing activities-534101-65232-2128232118219
Underwritten Equity Offering---------189--
At-The-Market Offering---------3620-
At-The-Market Offering---------3620-
Net cash provided by financing activities - continuing operations-----------220
Net cash used in financing activities - discontinued operations------------1
Net cash provided by financing activities-534101-65232-2128232118219
Effect of exchange rate changes on cash--------0-12-32
Net (decrease) increase in cash and cash equivalents--------402281-104-4
Operating Lease, Payments----------66
Cash paid for interest------2877109
Cash (paid) refunded for income taxes---------3-1611
Accrued capital expenditures--------2---
Accrued Royalty In Excess Of Minimum Payable To Sellers-------1618191616
Accrued Royalty In Excess Of Minimum Payable To Sellers-------1618191616